Format

Send to

Choose Destination
J Clin Microbiol. 2007 Jan;45(1):227-30. Epub 2006 Nov 8.

Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

Author information

1
JMI Laboratories, North Liberty, IA 52317, USA. ronald-jones@jmilabs.com

Abstract

Acinetobacter sp. isolates having multidrug resistance (MDR) patterns have become common in many medical centers worldwide, limiting therapeutic options. A five-center study tested 103 contemporary clinical Acinetobacter spp., including MDR strains, by reference broth microdilution and disk diffusion (15-mug disk content) methods against tigecycline. Applying U.S. Food and Drug Administration tigecycline breakpoint criteria for Enterobacteriaceae (susceptibility at < or =2 microg/ml [< or =1 microg/ml by the European Committee on Antimicrobial Susceptibility Testing]; disk diffusion breakpoints at > or =19 mm and < or =14 mm) to Acinetobacter spp. led to an unacceptable error rate (23.3%). However, an adjustment of tigecycline disk diffusion breakpoints (susceptible/resistant) to > or =16/ < or =12 mm reduced intermethod errors to an acceptable level (only 9.7%, all minor).

PMID:
17093026
PMCID:
PMC1828968
DOI:
10.1128/JCM.01588-06
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center